Palouse Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Palouse Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400	Closed	-$21.7K	–	122
2024 Q1	$21.7K	Buy	+400	New	+$20.4K	0.01%	125
2022 Q1	–	Sell	-90,553	Closed	-$5.65M	–	102
2021 Q4	$5.65M	Sell	90,553 -5,432	-6%	-$319K	2.41%	10
2021 Q3	$5.68M	Sell	95,985 -2,432	-2%	-$160K	2.52%	13
2021 Q2	$6.58M	Sell	98,417 -399	-0.4%	-$26K	2.87%	4
2021 Q1	$6.24M	Buy	98,816 +33,847	+52%	+$2.11M	2.75%	5
2020 Q4	$4.03M	Sell	64,969 -7,109	-10%	-$437K	2.13%	14
2020 Q3	$4.35M	Sell	72,078 -15,531	-18%	-$935K	2.43%	13
2020 Q2	$5.15M	Sell	87,609 -3,262	-4%	-$195K	2.72%	7
2020 Q1	$5.07M	Sell	90,871 -3,708	-4%	-$227K	2.99%	6
2019 Q4	$6.07M	Sell	94,579 -5,984	-6%	-$343K	2.3%	14
2019 Q3	$5.1M	Buy	+100,563	New	+$4.73M	1.89%	23

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Palouse Capital Management's BMY Position: Q2 2024 in Review

Palouse Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 400 shares — an estimated $21.7K sold.

Palouse Capital Management first reported a position in BMY in Q3 2019 and held it in 11 quarters. The position peaked at $6.58M in Q2 2021. 2,153 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Palouse Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Palouse Capital Management sold 400 Bristol-Myers Squibb shares in Q2 2024, an estimated $21.7K.
Palouse Capital Management first reported a position in Bristol-Myers Squibb in Q3 2019 and held it in 11 quarters.
Palouse Capital Management's Bristol-Myers Squibb position peaked at $6.58M in Q2 2021.
2,153 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Palouse Capital Management's 13F filing for Q2 2024, filed 12 Aug 2024.